Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | WDR5 | P61964 | 1/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6815365 | 0.88 | MAPT (0.67) | MAPTPOLBSLC6A9ALDH1A1SLC6A5 | |
| SCHEMBL20569608 | 0.87 | KMT2A (0.58) | MAPTPOLBSLC6A9ALDH1A1SLC6A5 | |
| SCHEMBL30309521 | 0.83 | L3MBTL1 (0.58) | L3MBTL1HRH4MAPTPOLBSLC6A9 | |
| SCHEMBL18775266 | 0.82 | L3MBTL1 (0.59) | L3MBTL1HRH4MAPTPOLBSLC6A9 | |
| SCHEMBL10519748 | 0.82 | POLB (0.77) | L3MBTL1HRH4MAPTPOLBALDH1A1 | |
| SCHEMBL30309424 | 0.81 | HRH4 (0.59) | L3MBTL1HRH4MAPTPOLBALDH1A1 | |
| SCHEMBL2306545 | 0.81 | L3MBTL1 (0.58) | L3MBTL1HRH4MAPTPOLBALDH1A1 | |
| SCHEMBL17979825 | 0.79 | L3MBTL1 (0.59) | L3MBTL1HRH4MAPTPOLBSLC6A9 | |
| SCHEMBL15286036 | 0.79 | HRH4 (0.49) | L3MBTL1HRH4POLBLMNAMEN1 | |
| SCHEMBL29959110 | 0.79 | NR1H2 (0.52) | L3MBTL1HRH4LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349588-A1 | 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-12-07 | — | — | US | disclosed |
| US-20170349588-A1 | 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-12-07 | — | — | US | disclosed |
| US-9765072-B2 | 1H-1,8-naphthyridin-2ones as anti proliferative compounds | NATCO PHARMA LIMITED (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765072-B2 | 1H-1,8-naphthyridin-2ones as anti proliferative compounds | NATCO PHARMA LIMITED (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170114057-A1 | 1H-1,8-NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| US-20170114057-A1 | 1H-1,8-NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| EP-3152205-A1 | 1H-1,8- NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | Natco Pharma Limited (IN) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015186137-A1 | 1H-1,8- NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015186137-A1 | 1H-1,8- NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2015-12-10 | — | — | WO | disclosed |
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | BOLD GUIDO | 2008-12-18 | — | — | US | disclosed |
| CN-101291917-A | Diaryl urea derivatives for the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2008-10-22 | — | — | CN | disclosed |
| EP-1689376-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051366-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349588-A1 | 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS | ABL1, MKI67, MCL1 | L3MBTL1 3134/4885HRH4 3413/4885MAPT 3385/4885 |
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | RET, PRKDC, PRKACA | L3MBTL1 2520/4885HRH4 1639/4885MAPT 450/4885 |
| US-20170114057-A1 | 1H-1,8-NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | ABL1, MKI67, ABL2 | L3MBTL1 3662/4885HRH4 3219/4885MAPT 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.